Artelo Biosciences Inc (ARTL)
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol ARTL. Based in Solana Beach, California, the company focuses on developing and commercializing therapies that act on lipid-signaling pathways. Its pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist being studied in a Phase 1b/2a trial for cancer-related anorexia; ART12.11, a cannabidiol and tetramethylpyrazine cocrystal under development for anxiety, depression, PTSD, epilepsy, insomnia, and related indications; and ART26.12, a fatty acid binding protein 5 inhibitor being evaluated for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, several cancer-related uses, pain, dermatologic conditions, and anxiety disorders. The company was incorporated in 2011 and adopted the Artelo Biosciences name in April 2017.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARTL
|
$1.62
|
43.8% Upside
|
Undervalued
|
$54 4,700.0% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-0.3x
|
0.6x
|
—
|
3.904 M
|
-5.72 M
|
15.6%
|
93.1%
|
-20.7
|
—
|
60.3%
|
